Welcome to our dedicated page for Envista Holdings SEC filings (Ticker: NVST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envista Holdings Corporation (NYSE: NVST) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its dental products business. As a Delaware-incorporated public company with common stock registered under Commission File Number 001-39054, Envista uses SEC filings to report on financial results, governance changes, and other material events related to its global family of dental brands.
On this page, investors can review Envista’s core periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s segments, such as Specialty Products & Technologies and Equipment & Consumables, along with risk factors, management discussion, and financial statements. Current reports on Form 8-K disclose specific developments, such as quarterly earnings releases, the publication of a Sustainability Report covering environmental, social, and governance topics, and changes in the composition of the Board of Directors.
Envista’s 8-K filings include items reporting results of operations and financial condition, where the company furnishes press releases detailing sales, net income, adjusted EBITDA, and business highlights for recent quarters. Other 8-K items address Regulation FD disclosures, such as slide decks used on earnings calls or references to sustainability and investor presentations, as well as board-level changes like the resignation of a director.
Through Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain key points in accessible language. Users can quickly identify the most relevant sections of Envista’s 10-K and 10-Q reports, understand the implications of 8-K announcements, and access information related to the company’s capital structure and governance. This page also serves as a starting point for tracking any future Forms 4 or proxy materials that may detail insider transactions or executive compensation, as they become available in Envista’s regulatory record.
Envista Holdings Corp (NVST) insider sale disclosure: Chief Financial Officer Eric D. Hammes reported the disposition of 7,654 shares of Envista common stock on 08/25/2025 at a reported price of $21.12 per share. After the transaction, Hammes beneficially owned 96,788 shares. The filing explains these shares were withheld to satisfy tax-withholding obligations related to the vesting of stock-settled Restricted Stock Units, indicating the transaction was not an open-market sale but a net settlement of equity awards. The Form 4 was signed by a power of attorney on 08/27/2025.
Stefan Nilsson, an officer and director of Envista Holdings Corp (NVST) and listed as President, Nobel Biocare, reported a routine disposition of the issuer's common stock. On 08/25/2025 Code F activity shows 804 shares were disposed at $21.12 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of stock-settled Restricted Stock Units. After this transaction Nilsson beneficially owned 54,941 shares in a direct ownership form. The Form 4 was signed by Heather Turner by power of attorney on 08/27/2025.
Envista Holdings Corp (NVST) reporting person Veronica Acurio, identified as President, Orthodontics and an officer/director, had 5,422 shares of common stock withheld to satisfy tax-withholding on vested restricted stock units. The transaction is reported as a disposition at an effective price of $21.12 per share on 08/25/2025, leaving 50,323 shares beneficially owned following the withholding.
This Form 4 describes a routine tax-related withholding tied to equity compensation rather than an open-market sale; no options, derivatives or other transactions are reported.
Envista Holdings Corp (NVST) insider sale reported. SVP of Strategy & Business Development Mischa Reis sold 15,000 shares of Envista common stock on 08/25/2025 at a price of $21.60 per share, reducing beneficial ownership to 32,382 shares. The filing states the sale was effected pursuant to a previously adopted Rule 10b5-1 trading plan. The Form 4 was signed by Heather Turner by power of attorney on 08/27/2025. The report lists no derivative transactions.
Envista Holdings Corporation (NVST) filed a Form 144 proposing the sale of 15,000 common shares through Fidelity Brokerage Services with an aggregate market value of $324,000. The filing reports 166,181,720 shares outstanding and an approximate sale date of 08/25/2025 on the NYSE. The 15,000 shares match a series of restricted stock vesting events received as compensation between 02/24/2020 and 02/25/2024, shown as multiple vesting lots totaling 15,000 shares. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Harris Associates L.P. and Harris Associates, Inc. report beneficial ownership of Envista Holdings Corp common stock representing 7,812,256 shares (4.6% of the class). Harris reports sole voting power over 6,182,724 shares and sole dispositive power over the full 7,812,256 shares, and states the holdings arise from advisory relationships with clients and are held in the ordinary course of business. The filing clarifies the position is not intended to change or influence control of the issuer.
Franklin Mutual Advisers, LLC (FMA) has disclosed a 5.3% passive stake in Envista Holdings Corp. (NYSE: NVST) via Schedule 13G. As of 30 Jun 2025, FMA beneficially owns 8,953,400 common shares, holding sole voting power over 8,498,236 shares and sole dispositive power over the full 8,953,400 shares. No shares are held with shared voting or dispositive authority, and no group filing is indicated. FMA is an SEC-registered investment adviser incorporated in Delaware.
The filing confirms the shares were acquired in the ordinary course of investment and not to influence control of Envista. Clients of FMA—including open-end funds and separate accounts—retain economic interest in the reported shares. The disclosure signals that a large institutional manager under the Franklin Resources umbrella has accumulated a >5% position, crossing the statutory threshold that triggers public reporting under Rule 13d-1(b). No financial performance metrics or strategic intentions are provided.